Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Elizabeth M. Mahoney is active.

Publication


Featured researches published by Elizabeth M. Mahoney.


JAMA | 2010

Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.

Deepak L. Bhatt; Kim A. Eagle; E. Magnus Ohman; Alan T. Hirsch; Shinya Goto; Elizabeth M. Mahoney; Peter W.F. Wilson; Mark J. Alberts; Ralph B. D'Agostino; Chiau Suong Liau; Jean Louis Mas; Joachim Röther; Sidney C. Smith; Genevieve Salette; Charles F. Contant; Joseph M. Massaro; Ph. Gabriel Steg

CONTEXT Clinicians and trialists have difficulty with identifying which patients are highest risk for cardiovascular events. Prior ischemic events, polyvascular disease, and diabetes mellitus have all been identified as predictors of ischemic events, but their comparative contributions to future risk remain unclear. OBJECTIVE To categorize the risk of cardiovascular events in stable outpatients with various initial manifestations of atherothrombosis using simple clinical descriptors. DESIGN, SETTING, AND PATIENTS Outpatients with coronary artery disease, cerebrovascular disease, or peripheral arterial disease or with multiple risk factors for atherothrombosis were enrolled in the global Reduction of Atherothrombosis for Continued Health (REACH) Registry and were followed up for as long as 4 years. Patients from 3647 centers in 29 countries were enrolled between 2003 and 2004 and followed up until 2008. Final database lock was in April 2009. MAIN OUTCOME MEASURES Rates of cardiovascular death, myocardial infarction, and stroke. RESULTS A total of 45,227 patients with baseline data were included in this 4-year analysis. During the follow-up period, a total of 5481 patients experienced at least 1 event, including 2315 with cardiovascular death, 1228 with myocardial infarction, 1898 with stroke, and 40 with both a myocardial infarction and stroke on the same day. Among patients with atherothrombosis, those with a prior history of ischemic events at baseline (n = 21,890) had the highest rate of subsequent ischemic events (18.3%; 95% confidence interval [CI], 17.4%-19.1%); patients with stable coronary, cerebrovascular, or peripheral artery disease (n = 15,264) had a lower risk (12.2%; 95% CI, 11.4%-12.9%); and patients without established atherothrombosis but with risk factors only (n = 8073) had the lowest risk (9.1%; 95% CI, 8.3%-9.9%) (P < .001 for all comparisons). In addition, in multivariable modeling, the presence of diabetes (hazard ratio [HR], 1.44; 95% CI, 1.36-1.53; P < .001), an ischemic event in the previous year (HR, 1.71; 95% CI, 1.57-1.85; P < .001), and polyvascular disease (HR, 1.99; 95% CI, 1.78-2.24; P < .001) each were associated with a significantly higher risk of the primary end point. CONCLUSION Clinical descriptors can assist clinicians in identifying high-risk patients within the broad range of risk for outpatients with atherothrombosis.


The New England Journal of Medicine | 2011

Quality of Life after PCI with Drug-Eluting Stents or Coronary-Artery Bypass Surgery

David J. Cohen; Ben van Hout; Patrick W. Serruys; Friedrich W. Mohr; Carlos Macaya; Peter den Heijer; M.M. Vrakking; Kaijun Wang; Elizabeth M. Mahoney; Salma Audi; Katrin Leadley; Keith D. Dawkins; A. Pieter Kappetein

BACKGROUND Previous studies have shown that among patients undergoing multivessel revascularization, coronary-artery bypass grafting (CABG), as compared with percutaneous coronary intervention (PCI) either by means of balloon angioplasty or with the use of bare-metal stents, results in greater relief from angina and improved quality of life. The effect of PCI with the use of drug-eluting stents on these outcomes is unknown. METHODS In a large, randomized trial, we assigned 1800 patients with three-vessel or left main coronary artery disease to undergo either CABG (897 patients) or PCI with paclitaxel-eluting stents (903 patients). Health-related quality of life was assessed at baseline and at 1, 6, and 12 months with the use of the Seattle Angina Questionnaire (SAQ) and the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). The primary end point was the score on the angina-frequency subscale of the SAQ (on which scores range from 0 to 100, with higher scores indicating better health status). RESULTS The scores on each of the SAQ and SF-36 subscales were significantly higher at 6 and 12 months than at baseline in both groups. The score on the angina-frequency subscale of the SAQ increased to a greater extent with CABG than with PCI at both 6 and 12 months (P=0.04 and P=0.03, respectively), but the between-group differences were small (mean treatment effect of 1.7 points at both time points). The proportion of patients who were free from angina was similar in the two groups at 1 month and 6 months and was higher in the CABG group than in the PCI group at 12 months (76.3% vs. 71.6%, P=0.05). Scores on all the other SAQ and SF-36 subscales were either higher in the PCI group (mainly at 1 month) or were similar in the two groups throughout the follow-up period. CONCLUSIONS Among patients with three-vessel or left main coronary artery disease, there was greater relief from angina after CABG than after PCI at 6 and 12 months, although the extent of the benefit was small. (Funded by Boston Scientific; ClinicalTrials.gov number, NCT00114972.).


Circulation | 2010

Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction TRITON-TIMI 38

Elizabeth M. Mahoney; Kaijun Wang; Suzanne V. Arnold; Irina Proskorovsky; Stephen D. Wiviott; Elliott M. Antman; Eugene Braunwald; David J. Cohen

Background— In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated that treatment with prasugrel versus clopidogrel was associated with reduced rates of cardiovascular death, MI, or stroke and an increased risk of major bleeding. We evaluated the cost-effectiveness of prasugrel versus clopidogrel from the perspective of the US healthcare system by using data from TRITON-TIMI 38. Methods and Results— Detailed resource use data were prospectively collected for all patients recruited from 8 countries (United States, Australia, Canada, Germany, Italy, Spain, United Kingdom, and France; n=3373 prasugrel, n=3332 clopidogrel). Hospitalization costs were estimated on the basis of diagnosis-related group and in-hospital complications. Cardiovascular medication costs were estimated by using net wholesale prices (clopidogrel=


Circulation-cardiovascular Quality and Outcomes | 2010

Vascular Hospitalization Rates and Costs in Patients With Peripheral Artery Disease in the United States

Elizabeth M. Mahoney; Kaijun Wang; Hong H. Keo; Sue Duval; Kim G. Smolderen; David J. Cohen; Gabriel Steg; Deepak L. Bhatt; Alan T. Hirsch

4.62/d; prasugrel=


Circulation-cardiovascular Quality and Outcomes | 2008

One-Year Costs in Patients With a History of or at Risk for Atherothrombosis in the United States

Elizabeth M. Mahoney; Kaijun Wang; David J. Cohen; Alan T. Hirsch; Mark J. Alberts; Kim A. Eagle; Frederique Mosse; Joseph Jackson; P. Gabriel Steg; Deepak L. Bhatt

5.45/d). Life expectancy was estimated from in-trial cardiovascular and bleeding events with the use of statistical models of long-term survival from a similar population from the Saskatchewan Health Database. Over a median follow-up of 14.7 months, average total costs (including study drug) were


Journal of the American College of Cardiology | 2002

Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation ☆

Elizabeth M. Mahoney; Trevor D. Thompson; Emir Veledar; Jovonne K. Williams; William S. Weintraub

221 per patient lower with prasugrel (95% confidence interval, −759 to 299), largely because of a lower rate of rehospitalization involving percutaneous coronary intervention. Prasugrel was associated with life expectancy gains of 0.102 years (95% confidence interval, 0.030 to 0.180), primarily because of the decreased rate of nonfatal MI. Thus, compared with clopidogrel, prasugrel was an economically dominant treatment strategy. If a hypothetical generic cost for clopidogrel of


Circulation-cardiovascular Quality and Outcomes | 2009

Economic Impact of Angina After an Acute Coronary Syndrome Insights From the MERLIN-TIMI 36 Trial

Suzanne V. Arnold; David A. Morrow; Yang Lei; David J. Cohen; Elizabeth M. Mahoney; Eugene Braunwald; Paul S. Chan

1/d is used, the incremental net cost with prasugrel was


Circulation | 2003

Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial.

Zefeng Zhang; Elizabeth M. Mahoney; Rodney H. Stables; Jean Booth; Fiona Nugara; John A. Spertus; William S. Weintraub

996 per patient, yielding an incremental cost-effectiveness ratio of


Circulation | 2005

Cost-Effectiveness of Eplerenone Compared With Placebo in Patients With Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure

William S. Weintraub; Zefeng Zhang; Elizabeth M. Mahoney; Paul Kolm; John A. Spertus; J. Jaime Caro; Jack Ishak; Robert J. Goldberg; Joseph Tooley; Richard J. Willke; Bertram Pitt

9727 per life-year gained. Conclusion— Among acute coronary syndrome patients with planned percutaneous coronary intervention, treatment with prasugrel versus clopidogrel for up to 15 months is an economically attractive treatment strategy. Clinical Trial Registration— clinicaltrials.gov. Unique identifier: NCT00097591.


American Journal of Cardiology | 1999

Influence of age on outcome after percutaneous transluminal coronary angioplasty

Claudia F Gravina Taddei; William S. Weintraub; John S. Douglas; Ziyad Ghazzal; Elizabeth M. Mahoney; Trevor D. Thompson; Spencer B. King

Background—Peripheral artery disease (PAD) is common and imposes a high risk of major systemic and limb ischemic events. The REduction of Atherothrombosis for Continued Health (REACH) Registry is an international prospective registry of patients at risk of atherothrombosis caused by established arterial disease or the presence of ≥3 atherothrombotic risk factors. Methods and Results—We compared the 2-year rates of vascular-related hospitalizations and associated costs in US patients with established PAD across patient subgroups. Symptomatic PAD at enrollment was identified on the basis of current intermittent claudication with an ankle-brachial index (ABI) <0.90 or a history of lower-limb revascularization or amputation. Asymptomatic PAD was diagnosed on the basis of an enrollment ABI <0.90 in the absence of symptoms. Overall, 25 763 of the total 68 236–patient REACH cohort were enrolled from US sites; 2396 (9.3%) had symptomatic and 213 (0.8%) had asymptomatic PAD at baseline. One- and cumulative 2-year follow-up data were available for 2137 (82%) and 1677 (64%) of US REACH patients with either symptomatic or asymptomatic PAD, respectively. At 2 years, mean cumulative hospitalization costs, per patient, were

Collaboration


Dive into the Elizabeth M. Mahoney's collaboration.

Top Co-Authors

Avatar

William S. Weintraub

Christiana Care Health System

View shared research outputs
Top Co-Authors

Avatar

David J. Cohen

University of Missouri–Kansas City

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yang Lei

University of Missouri–Kansas City

View shared research outputs
Top Co-Authors

Avatar

Kaijun Wang

University of Missouri–Kansas City

View shared research outputs
Top Co-Authors

Avatar

John A. Spertus

University of Missouri–Kansas City

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Deepak L. Bhatt

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Eugene Braunwald

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Emir Veledar

Baptist Hospital of Miami

View shared research outputs
Researchain Logo
Decentralizing Knowledge